. Author manuscript; available in PMC: 2014 May 17.

Published in final edited form as: Eur J Nucl Med Mol Imaging. 2013 Nov 23;41(2):369–383. doi: 10.1007/s00259-013-2569-6

Table 3. Multiple Linear Regression Analyses with Backward Elimination and Enter Analysis to Identify Variables Potentially Impacting the FDG Blood Pool Activity in the SVC and JV.

_meanSUV_mean was the response variables and body mass index (BMI), statin medication, diabetes, anti-diabetic drugs, injected FDG dose, FDG circulation time_Chest or FDG circulation time_Neck, respectively, and continuous- or classified pre-scan fasting glucose values, respectively, were the explanatory variables. Variables were retained in the model when p < 0.10 and entered afterwards the Enter Analysis. In that model, variables were judged to be statistically significant when p < 0.05. β is the standardized regression coefficient.

SVC (Continuous Pre-scan Fasting Glucose Values)
Backward Analysis _meanSUV_mean
Explanatory Variables: BMI, Statin Medication, Diabetes, Anti-diabetic Drugs, Injected FDG Dose, FDG Circulation Time_Chest, Pre-scan Fasting Glucose
Enter Analysis _meanSUV_mean
Explanatory Variables: FDG Circulation Time_Chest, Pre-scan Fasting Glucose, Anti-diabetic Drugs, Statin Medication, BMI
	Standardized Coefficient β	95 % Confidence Interval	Adjusted R²	Significance	*p - value*
			0.268	< 0.0001
FDG Circulation Time_Chest	−0.501	−0.007 – −0.004			< 0.0001
Pre-scan Fasting Glucose	0.174	0.000 – 0.003			0.021
Anti-diabetic Drugs	−0.173	−0.156 – −0.011			0.024
SVC (Classified Pre-scan Fasting Glucose Values)
Backward Analysis _meanSUV_mean
Explanatory Variables: BMI, Statin Medication, Diabetes, Anti-diabetic Drugs, Injected FDG Dose, FDG Circulation Time_Chest, Pre-scan Fasting Glucose < 6.1 mmol/l, Pre-scan Fasting Glucose ≥ 6.1 mmol/l < 7.0 mmol/l, Pre-scan Fasting Glucose ≥ 7.0 mmol/l
Enter Analysis _meanSUV_mean
Explanatory Variables: FDG Circulation Time_Chest, Statin Medication, Anti-diabetic Drugs, BMI, Pre-scan Fasting Glucose ≥ 7.0 mmol/l
	Standardized Coefficient β	95 % Confidence Interval	Adjusted R²	Significance	*p - value*
			0.260	< 0.0001
FDG Circulation Time_Chest	−0.499	−0.007 – −0.004			< 0.0001
Statin Medication	0.152	0.005 – 0.124			0.033
Anti-diabetic Drugs	−0.169	−0.157 – −0.007			0.033
BMI	0.139	0.000 – 0.010			0.042
JV (Continuous Pre-scan Fasting Glucose Values)
Backward Analysis _meanSUV_mean
Explanatory Variables: BMI, Statin Medication, Diabetes, Anti-diabetic Drugs, Injected FDG Dose, FDG Circulation Time_Neck, Pre-scan Fasting Glucose
Enter Analysis _meanSUV_mean
Explanatory Variables: BMI, FDG Circulation Time_Neck
	Standardized Coefficient β	95 % Confidence Interval	Adjusted R²	Significance	*p - value*
			0.179	< 0.0001
BMI	0.371	0.008 – 0.017			< 0.0001
FDG Circulation Time_Neck	−0.210	−0.003 – 0.000			0.002
JV (Classified Pre-scan Fasting Glucose Values)
Backward Analysis _meanSUV_mean
Explanatory Variables: BMI, Statin Medication, Diabetes, Anti-diabetic Drugs, Injected FDG Dose, FDG Circulation Time_Neck, Pre-scan Fasting Glucose < 6.1 mmol/l, Pre-scan Fasting Glucose ≥ 6.1 mmol/l < 7.0 mmol/l, Pre-scan Fasting Glucose ≥ 7.0 mmol/l
Enter Analysis _meanSUV_mean
Explanatory Variables: BMI, FDG Circulation Time_Neck
	Standardized Coefficient β	95 % Confidence Interval	Adjusted R²	Significance	*p - value*
			0.179	< 0.0001
BMI	0.371	0.008 – 0.017			< 0.0001
FDG Circulation Time_Neck	−0.210	−0.003 – 0.000			0.002